Storage correction in cells of patients suffering from mucopolysaccharidoses types IIIA and VII after treatment with genistein and other isoflavones
- 327 Downloads
Mucopolysaccharidoses are autosomal and recessive lysosomal storage disorders caused by the deficiency of a lysosomal enzyme involved in glycosaminoglycan catabolism. The Sanfilippo type A disease (MPS III A) results from sulfamidase deficiency, which leads to accumulation of heparan sulfate, whereas Sly disease (MPS VII) results from beta-glucuronidase deficiency, leading to accumulation of heparan, dermatan, and chondroitin sulfates. These syndromes are characterized by severe central nervous system degeneration, resulting in progressive mental retardation, and fatality occurs in severely affected children. To date, no effective treatment is available except for bone marrow transplantation in specific cases. Recently, the use of genistein, an isoflavone that inhibits glycosaminoglycans synthesis, has been tested as substrate reduction therapy for neuronopathic forms of these diseases. We tested five natural analogs to genistein in human fibroblasts from both Sanfilippo A and Sly patients. Four molecules were as efficient as genistein in decreasing glycosaminoglycan accumulation. Moreover, a combination of several isoflavones was more efficient than one single isoflavone, suggesting a synergistic effect. These preliminary data may offer new perspectives for treating Sly and Sanfilippo A diseases and could be relevant to other neurological forms of mucopolysaccharidoses.
KeywordsGenistein Isoflavones Daidzein Formononetin Glycitein
Lysosomal storage disease
Central nervous system
Enzyme replacement therapy
Substrate deprivation therapy
Substrate reduction therapy
We thank C. Caillaud for providing human fibroblasts derived from healthy volunteers. We also thank very much G. Chabot for all his advices regarding the isoflavone selection. This work was supported by the 6th PCRDT European “CLINIGENE” Network of Excellence and the MOLEDA STREP. A.A. received sponsorship from CLINIGENE.
- Harmatz P, Giugliani R, Schwartz I et al, MPS VI Phase 3 Study Group (2006) Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. J Pediatr 148(4):533–539CrossRefGoogle Scholar
- Jakóbkiewicz-Banecka J, Piotrowska E, Narajczyk M, Barańska S, Wegrzyn G (2009) Genistein-mediated inhibition of glycosaminoglycan synthesis, which corrects storage in cells of patients suffering from mucopolysaccharidoses, acts by influencing an epidermal growth factor-dependent pathway. J Biomed Sci 16:26CrossRefPubMedGoogle Scholar
- Neufeld E, Muenzer J (2001) The mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Kinzler KW, Vogelstein B (eds) The metabolic and molecular bases of inherited disease, 8th edn. McGraw-Hill, New York, pp 3421–3452Google Scholar
- Piotrowska E, Jakóbkiewicz-Banecka J, Barańska S, Tylki-Szymańska A, Czartoryska B, Wegrzyn A, Wegrzyn G (2006) Genistein-mediated inhibition of glycosaminoglycan synthesis as a basis for gene expression-targeted isoflavone therapy for mucopolysaccharidoses. Eur J Hum Genet 14(7):846–852CrossRefPubMedGoogle Scholar
- Piotrowska E, Jakóbkiewicz-Banecka J, Tylki-Szymanska A, Libereck A, Maryaniak A, Malinowska M, Czartoryska B, Puk E, Kloska A, Libereck T, Barańska S, Wegrzyn A, Wegrzyn G (2008) Genistein-rich soy isoflavone extract in substrate reduction therapy for Sanfilippo Syndrome: an open-label, pilot study in 10 pediatric patients. Curr Ther Res 69(2):166–179CrossRefGoogle Scholar
- Piotrowska E, Jakóbkiewicz-Banecka J, Wegrzyn G (2009) Different amounts of isoflavones in various commercially available soy extracts in the light of gene expression-targeted isoflavone therapy. Phytother Res [Epub ahead of print].Google Scholar